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Abstract
Introduction. The possibility that variation in packaging and pill appearance may reduce 
adherence is a reason for concern, especially for chronic diseases. The objectives of the 
study were to quantify the extent of switches between generic antidiabetics and to verify 
whether switching between different products of the same substance affects adherence.
Materials and methods. All elderly residents of the Umbria Region who received at least 
2 prescriptions of antidiabetics in 2010 and 2011 were included in the study. Switching 
was defined as the dispensing of two different products of the same substance in a series 
of two prescriptions. Single and multiple switchers were identified according to the num-
ber of switches during 2011. Switching relevant to the three off-patent substances with 
generic use ≥ 5% (metformin, gliclazide and repaglinide) was quantified. The effect of 
switching on adherence, defined as the proportion of days in 2011 covered by prescrip-
tions (Medication Possession Ratio, MPR), was estimated.
Results. Among the 15 964 patients receiving antidiabetics (14.4% of the elderly popu-
lation) 9211 were prescribed at least one of the generic substances. Of these patients, 
23.3% experienced a single switch and 15.7% were multiple switchers (61.0% never 
switched). The proportion of multiple switchers increased with the number of prescrip-
tions, reaching 26% among patients with ≥ 11 prescriptions. MPR was 62%, 62% and 
72%, respectively among non-switchers, single and multiple switchers.
Conclusions. In elderly patients treated with antidiabetics, the substitution between 
branded and unbranded products (as well as between generics) of the same substance, 
did not negatively affect adherence.
INTRODUCTION
Treatment adherence is a well-known predictor 
of clinical outcome. Several factors, such as ageing, 
comorbidities and polypharmacy, may in turn affect 
adherence and influence the outcome of treatments 
[1-6]. 
Diabetes in the elderly population is an ideal set-
ting to study adherence and the characteristics that 
may modify the continuity of treatment. The disease 
affects a large proportion of the population (in Italy, 
more than 5% of the general population and about 
20% of the elderly ≥ 75 years old) [7]; several anti-
diabetics are often required to control the disease [8, 
9]; and most of the patients present co-morbidities 
for which many pharmacological treatments are indi-
cated [6, 10, 11]. 
Even though the use of generics is an important 
opportunity to reduce health care expenditure, there 
is a concern it may affect the attitude of patients in 
following the prescribed indications. A specific rea-
son for attention was raised on the effect of generic 
substitution (i.e., switches between brand names and 
generics, and switches between generics), especially 
among elderly who receive many different substances 
for prolonged periods of time. The change in package 
appearance each time a new prescription is dispensed 
may create confusion and ultimately reduce patients’ 
adherence [12, 13]. The issue is of great relevance for 
a chronic condition such as diabetes, since pharma-
cological treatments include different substances and 
different packages (of all branded/generic products) 
of the same substance.
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Few studies estimated the frequency of substitu-
tion between generics of the same substance [14-16] 
and there are controversial findings on the effect of 
switching between generics on treatment adherence 
[17-21]. Moreover, no study has been conducted in 
the diabetes setting.
The objectives of the study were to quantify the ex-
tent of switches between generic antidiabetics and to 
verify whether switching between different products 
of the same substance affects adherence.
MATERIALS AND METHODS
Study population
The study was conducted in the population of the 
Umbria Region (907 000 inhabitants in 2011), Ita-
ly. All residents are covered by the Italian National 
Health Service (NHS), which provides comprehen-
sive hospital and outpatient care.
Outpatients receive prescriptions from General 
Practitioners (GPs) and obtain medicines covered 
by the NHS from local community pharmacies or 
in some cases directly from local health units (both 
types of distribution were considered for the analy-
sis). For each prescription, the following information 
is available at regional level: patient code (which is 
anonymized before any subsequent use), date of pre-
scription, drug substance, marketing authorization 
code (indicating the specific brand or generic prod-
ucts), number of packages. Prescription data were 
linked through the anonymized code to the regional 
database of enrollees to retrieve age and gender. No 
information is available on prescriptions issued during 
the hospitalization and on medicines use in nursing 
homes. 
The eligible population included the elderly aged 
≥ 75 years who were resident in the Region in 2010 
and 2011. Patients were considered to be on treat-
ment with antidiabetics if they had filled at least two 
prescriptions of antidiabetics (identified through the 
international Anatomical Therapeutic Chemical clas-
sification system, ATC code A10) both in 2010 and 
2011. Furthermore, to ensure that subjects were still 
using health care services at the end of 2011, patients 
were required to have at least a prescription (of any 
drug) during the last trimester of 2011. Subjects who 
met the eligibility criteria were included in the study 
cohort to investigate the utilization patterns of anti-
diabetics in 2011.
Therapeutic categories and indicators for usage
The following classes of antidiabetics were consid-
ered: i) insulins (ATC A10A); ii) biguanides (ATC 
A10BA); iii) sulphonamides (ATC A10BB); iv) glita-
zones (ATC A10BG); v) dipeptidyl peptidase-4 (DPP-
4) inhibitors (ATC A10BH); vi) alpha-glucosidase in-
hibitors (ATC A10BF); vii) fixed-dose combinations 
(ATC A10BD); viii) other blood glucose lowering 
drugs (ATC A10BX).
All other prescriptions (different from antidiabet-
ics) issued during 2011 were classified according to 
pre-specified 15 clinical subgroups (Supplementary Ta-
ble S1, available online at www.iss.it/anna) in order to: i) 
identify co-morbidities associated with diabetes (e.g., 
users of antihypertensives, antiparkinsons); ii) quanti-
fy the extent of polytherapy, defined as the number of 
different substances at the Vth ATC level (other than 
antidiabetics) prescribed during 2011.
The list of off-patent drugs, both originator and 
copies, marketed in Italy is regularly updated by the 
Italian Medicines Agency [22]. Off-patent medicines 
were classified as branded and unbranded. Branded 
products are defined as medicines sold under a pro-
prietary name, whereas unbranded generics are sold 
under their international non-proprietary name (i.e., 
the name of the substance). 
Drug consumption was evaluated in terms of: pre-
scriptions received; number of packages; total gross 
expenditure; and defined daily doses (DDDs: the 
daily maintenance dose for the main indication in 
adults). Two indicators of drug use were calculated: 
the prevalence of use (by dividing the number of drug 
users by the overall resident population); the DDDs 
per 1000 users per day (the mean number of doses 
consumed every day by 1000 patients included in the 
cohort). 
Identification of switches
Only generic antidiabetics with a use of generics 
≥ 5% (in terms of DDDs for each substance) were 
considered for the analysis of switches. Only patients 
filling at least 2 prescriptions of the same substance 
during 2011 were included. The dispensing date of 
the first prescription of an off-patent antidiabetic in 
2011 was the index date. 
Switches were defined as the dispensing of two 
different products (any of the brand and unbranded 
packages) of the same substance in a series of two 
prescriptions in 2011. Three main switching catego-
ries were defined:
• no switch: patients who received the same products 
during the entire follow up; 
• single switch: patients who experienced only one 
switch (from A to B) or who had a total of two switch-
es involving a switch back to the first product (from 
A to B to A);
• multiple switch: patients with three or more switch-
es, as well as two switches within three different prod-
ucts (from A to B to C).
Adherence to the antidiabetic therapy
Adherence to the generic antidiabetics included 
in the analysis was determined using the medication 
possession ratio (MPR) calculated by dividing the 
theoretical duration of the prescription (we assumed 
that 1 prescription covered 30 days of therapy) by the 
number of days between the first and last prescription 
(plus the days covered by the last prescription).
RESULTS
Descriptive analysis of the selected cohort
In the Umbria Region, 15 964 subjects ≥ 75 years 
(14.4% of the elderly population) received at least 2 
prescriptions of antidiabetics per year in 2010-2011 
and were included in the study (Table 1). Antidiabet-
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ics represented 21.5% of the per capita pharmaceuti-
cal expenditure (200 out of 931 euro) and 20% of the 
DDDs prescribed in this population. 
In addition to antidiabetics, each subject received a 
median of 10 different substances during 2011, high-
lighting a high level of polypharmacy, and 25% of the 
diabetic patients was treated with at least 14 substanc-
es (Table 1). Only 1% of the diabetic patients (147 out 
of 15 964) received no prescriptions in addition to an-
tidiabetics (thus considered as having no comorbidi-
ties), whereas more than 80% received prescriptions 
in at least three different therapeutic categories. Anti-
hypertensives and antiaggregants-anticoagulants were 
the most frequently prescribed drugs (prevalence of 
use 90.2% and 69.3% respectively) (Table 1). This level 
of use, together with the proportion of patients re-
ceiving lipid-lowering drugs (42.0%), suggests cardio-
vascular diseases as the principal comorbidity in this 
diabetic cohort. Drugs acting on the nervous system 
(i.e. antidepressants, pain medications and antipsy-
chotics) were frequently prescribed, identifying the 
group of nervous and psychiatric disorders as the sec-
ond chronic comorbidity. A further 20.2% of diabetic 
patients received prescriptions of respiratory drugs.
Gender did not influence the prescription patterns 
of antidiabetics, whereas the increasing age had a 
negative association with prevalence of use (Table 1) 
and DDDs/1000 users-die (data not shown). Most 
of the antidiabetic prescriptions concerned patented 
medicines (68%), whereas the remaining 32% consist-
ed of branded (20%) and unbranded generics (12%). 
Metformin was the most frequently prescribed an-
tidiabetic (prevalence of use 6.8%), followed by insu-
lins (5.1%) and sulphonamides (3.5%) (Table 2). Very 
few patients were treated with newer oral antidiabetic 
agents such as a DPP-4 inhibitors or pioglitazone 
(prevalence of use, 0.1% for each class). 
During 2011 each patient received an average of 12 
prescriptions of antidiabetics (i.e. 1 prescription per 
month) corresponding to 17 drug packages per year 
(1.4 packages per month) and around 1.1 doses per 
day, which is coherent with a treatment model of a 
chronic diseases (Table 2). These data suggest that el-
derly diabetic patients were followed up monthly by 
GPs and that each prescription of antidiabetics typi-
cally covered 1 month of treatment. The yearly cost of 
treatment per user varied among drug classes, from a 
minimum of 33-42 euro for metformin and sulphona-
mides to 327-406 euro for DPP-4 inhibitors and insu-
lins (Table 2). 
Most of the patients (51.4%) received only one an-
tidiabetic drug and, within monotherapy, 41% were 
users of metformin. The proportion of patients receiv-
ing two antidiabetics during 2011 was 35.7%, and the 
remaining 12.9% were prescribed more than two an-
tidiabetics.
Among antidiabetics, generics were only available 
for metformin, gliclazide, glimepiride, and repaglinide 
(Table 2). The use of unbranded generics was higher 
for gliclazide and repaglinide (61% and 48% of the 
DDDs) whereas it represented only 3% of the DDDs 
of glimepiride. The number of generic products mar-
keted in Italy ranged from 4 for repaglinide to 18 for 
gliclazide. 
Analysis of switching among generics 
and its impact on adherence
The analysis was conducted on the 9211 patients 
receiving at least one of the three substances availa-
ble as generics: metformin, gliclazide and repaglinide 
(glimepiride was excluded since 97% of the prescrip-
tions were still relevant to the branded originator). 
The majority of diabetic patients (61.0%) did not 
switch during the year. The proportion of non-switchers 
was similar for the three substances, ranging from 62.5% 
with metformin to 57.9% with repaglinide (Table 3). Pa-
Table 1
Characteristics of the antidiabetics users included 
in the study cohort
Total subjects, N (prevalence, %) 15 964 (14.4)
Gender, N (prevalence, %)
Male 6550 (15.4) 
Female 9414 (13.9) 
Age class, N (prevalence, %)
75-79 y 6400 (14.9) 
80-84 y 5276 (15.0) 
85-89 y 3115 (13.6) 
≥ 90 y 1173 (12.2) 
Total drug expenditure (euro) 931
DDDs/1000 users-die
Antidiabetics 1078
Any drugs (including antidiabetics) 5588
Median number of substances prescribed 
in 2011 in addition to antidiabetics (IQR) 10 (7-14)
Drug classes most frequently prescribed 
in 2011 in addition to antidiabetics, 
% of users*
Antihypertensives 90.2
Antiaggregants/Anticoagulants 69.3
Antibiotics 60.7
Antacids-Antiulcer drugs 54.4
Lipid lowering drugs 42.0
NSAIDs 37.4
Antidepressants 22.5
Respiratory drugs 20.2
Pain medications (opioids) 18.0
Prostate medication 13.9
Antiglaucoma drugs 11.3
Thyroid medications 8.5
Antipsychotics 5.2
Antiparkinsons 5.2
Osteoporosis medications 4.7
*: for details on the drug classes definitions see Table S1.
DDD: defined daily dose; IQR: interquartile range.
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Metformin Gliclazide Repaglinide
No 
switch
Single 
switch
Multiple 
switch
No 
switch
Single 
switch
Multiple 
switch
No 
switch
Single 
switch
Multiple 
switch
Subjects 4515 (62.5)
1318 
(18.2)
1389 
(19.2)
1166 
(62.3)
459 
(24.5)
246 
(13.1)
977
(57.9)
458 
(27.2)
251 
(14.9)
Gender          
Male 1842 (60.5)
591
(19.4)
612 
(20.1)
437
(59.8)
195 
(26.7)
99
(13.5)
386 
(55.6)
195 
(28.1)
113 
(16.3)
Female 2573 (64.0)
727
(17.4)
777 
(18.6)
729
(63.9)
264 
(23.2)
147 
(12.9)
591 
(59.6)
263 
(26.5)
138 
(13.9)
Age groups          
75-79 2162 (63.5)
606 
(17.8)
637 
(18.7)
445 
(62.7)
171 
(24.1)
94 
(13.2)
390 
(57.8)
178 
(26.4)
107 
(15.9)
80-84 1480 (62.4)
406 
(17.1)
484 
(20.4)
380 
(60.8)
164 
(26.2)
81 
(13.0)
338 
(57.5)
165 
(28.1)
85 
(14.5)
85-89 668 (59.9)
238 
(21.3)
210 
(18.8)
253 
(64.7)
81 
(20.7)
57 
(14.6)
191 
(59.7)
82 
(25.6)
47 
(14.7)
90+ 205 (61.9)
68
(20.5)
58 
(17.5)
88 
(60.7)
43 
(29.7)
14 
(9.7)
58 
(56.3)
33 
(32.0)
12 
(11.7)
Number of thera-
peutic categories*          
0 38 (66.7)
7 
(12.3)
12 
(21.1)
20 
(74.1)
5 
(18.5)
2 
(7.4)
5 
(29.4)
8 
(47.1)
4 
(23.5)
1-2 631 (65.5)
163 
(16.9)
169 
(17.5)
162 
(58.5)
71 
(25.6)
44 
(15.9)
117 
(56.8)
57 
(27.7)
32 
(15.5)
≥3 3846 (62.0)
1148 
(18.5)
1208 
(19.5)
984 
(62.8)
383 
(24.4)
200 
(12.8)
855 
(58.4)
393 
(26.9)
215 
(14.7)
Median switches 
of multiple 
switchers (IQR)
  4 (3-5)   3 (3-4)   3 (3-5)
*: for the definition of therapeutic categories see table S1; IQR: interquartile range.
ATC 
code
Prevalence 
of use (%)
Prescriptions/
users
Packages/
users
Cost/
users %DDD %DDD %DDD
Patented Branded Unbranded
Biguanides 
Metformin A10BA02 6.8 9 15 33 - 64 36
Insulins A10A 5.1 8 9 406 100 - -
Sulphonamides A10BB 3.5 8 11 42 9 59 32
Gliclazide A10BB09 1.8 7 9 50 - 39 61
Glimepiride A10BB12 1.3 8 11 29 - 97 3
Fixed-dose combinations A10BD 2.5 9 15 86 80 20 -
Other blood glucose 
lowering drugs A10BX 1.7 7 8 77 2 51 47
Repaglinide A10BX02 1.7 7 8 68 - 52 48
Alpha glucosidase 
inhibitors (i.e. acarbose) A10BF 0.3 8 11 90 100 - -
Glitazones
(i.e. pioglitazone) A10BG 0.1 8 9 225 100 - -
DPP-4 inhibitors A10BH 0.1 6 7 327 100 - -
Total  14.4 12 17 200 68 20 12
ATC: anatomical therapeutic chemical classification; DDD: defined daily dose; DPP-4 inhibitors: Dipeptidyl peptidase-4 inhibitors.
Table 3
Characteristics of patients treated with generic antidiabetics by category of switching. For each characteristics the total number of pa-
tients may be obtained by adding the number of patients in the three switching categories (no switch; single switch; multiple switch)
Table 2
Use of antidiabetics by drug class in 2011. Substances available as generics are reported in italics
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tients with a single switch ranged from 27.2% for re-
paglinide to 18.2% for gliclazide. Multiple switches 
were observed on average in 15.7% of the patients 
and the median number of switches was comparable 
for the three selected antidiabetics. The likelihood of 
switching did not vary by gender, age subgroups and 
number of therapeutic categories (especially when 
taking into account that only a few patients were in-
cluded in some categories).
The probability of switching rises with the increas-
ing number of prescriptions for the same substance 
(Figure 1). The proportion of non-switchers was on av-
erage 78% in the group receiving 2-3 prescriptions and 
progressively decreased up to an average of 56% in 
case of 11 or more prescriptions. The opposite trend 
was observed for multiple switchers with a maximum 
of 26% among subjects with ≥ 11 prescriptions. The 
proportion of patients with a single switch (about 20% 
of the users) was relatively stable with the increasing 
number of prescriptions. 
Switches between generic antidiabetics did not im-
pact negatively on treatment adherence (Figure 2). 
Similar level of adherence were observed across the 
three switching categories for the three substances 
(metformin, gliclazide and repaglinide). Overall, the 
median MPR was 62%, 62%, and 72% among non-
switchers, single and multiple switchers respectively 
(Figure 2d). Since the number of prescriptions is as-
sociated with both the probability of switching and 
treatment adherence, we also restricted the analysis 
to patients who received more than 5 prescriptions. 
The differences between the three switching catego-
ries were even smaller, with the median MPR ranging 
from 75% to 77% (Supplementary Figure S1, available 
online at www.iss.it/anna). 
DISCUSSION
The possibility that variation in packaging and pill 
appearance may affect adherence is a reason for con-
cern. For instance, Kesselheim and colleagues [17] 
showed, in a recent article, that changes in pill colors 
and shapes increased the risk of non-adherence among 
epileptic patients. If this effect were confirmed, sub-
stituting patented originators with generic alterna-
tives, as well as switching between different generics, 
may carry a risk for patients’ outcome, especially in 
case of chronic diseases.
Our study does not support this concern. In the en-
tire elderly population of patients who received anti-
diabetics in the Umbria Region, the substitution be-
tween branded and unbranded product, as well as be-
tween generics, did not negatively affect adherence.
For the three antidiabetics with a generic equiva-
lent included in our analysis, 61.0% of the patients 
received the same package during the year (non-
switchers) and 23.3% experienced only one package 
substitution (single switch). As expected, the likeli-
hood of any switching increased  with the number of 
prescriptions. Among patients with more than 11 pre-
scriptions (of each substance), 18% did switch once, 
and 26% experienced multiple switching (if combined 
44% of patients did switch at least once during the 
year). On one hand, the likelihood of switching was 
not influenced by patients’ characteristics such as 
age, sex and number of therapeutic categories. On 
the other hand, non-switchers, patients with a single 
switch and multiple switchers, were equally likely to 
adhere to the antidiabetic treatment where a generic 
is available. Adherence data by intensity of switching 
were consistent for the three substances (metformin, 
repaglinide and gliclazide), thus suggesting that these 
findings may apply to other off-patented drugs and 
generic substitutions. 
In the only comparable analysis, Kalisch et al. [15] 
investigated the generic substitution of metformin; the 
majority of patients were non-switchers, 14% received a 
single switch and 7% were multiple switchers. Our find-
ings are also comparable with others that focused on 
different chronic therapies (e.g., calcium channel block-
ers, selective serotonin reuptake inhibitors, statins) [15, 
16]. Around 80% of patients were non-switchers or ex-
perienced a single switch, and the proportion of multi-
ple switchers ranged between 19 and 24%. 
Our results are also coherent with others in the 
cardiovascular setting and in postmenopausal women 
with osteoporosis: adherence was not found to be in-
fluenced by generic switches among antihypertensive 
agents and alendronate, respectively [18-21]. Howev-
er, in specific settings such as those involving psychiat-
ric and neurological conditions, the effects of generic 
substitution are still unclear. In particular, two studies 
by Hartung et al. [23] and Duh et al. [24] investigated 
the effect of generic substitution of antiepileptics on 
a clinical outcome (i.e. the rate of hospitalization) and 
showed opposite findings. 
The cohort of patients included in our study can 
be considered representative of an elderly popula-
tion with diabetes. The proportion of patient receiv-
ing either a single antidiabetic (considered as a proxy 
of monotherapy) or two substances (considered as a 
proxy of dual therapy) is consistent with the published 
literature [11, 25, 26]. Also the proportion of patients 
treated with metformin as monotherapy is similar to 
that found in other countries [27-31]. Newer drugs 
such as DPP-4 inhibitors were prescribed to a minor-
ity of patients. Diabetes represents a good example of 
a chronic condition. On average, each patient includ-
ed in the study received more than 5 daily doses of any 
drug (5588 DDDs per 1000 subjects per day) and, 
in addition to antidiabetics, a median of 10 different 
substances during the year. The type of comorbidities 
identified through prescriptions, their estimated fre-
quency, as well as the high rate of polypharmacy fully 
reflect findings of other reports [25, 32-35].
As for other studies that used prescription data-
bases, a limitation of our analysis is that the calcu-
lation of adherence depended on pharmacy records. 
For instance, prescriptions may overestimate adher-
ence if a drug is collected but not used. Furthermore, 
we calculated the MPR assuming that 1 prescription 
covers 1 month of therapy, which may slightly modify 
the estimates, but is not expected to impact on the 
comparisons between the three switching categories. 
It should be pointed out that the MPR in our study 
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Figure 1
Distribution of switching categories by number of prescriptions.
Figure 2
Adherence comparison by switching categories.
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was only adopted to perform comparisons between 
the switching categories of the same substance. As 
indicated before, a diabetic patient may receive more 
than 1 antidiabetic (including more than 1 generic 
substance included in the analysis). The prescription 
database only covers prescriptions issued to outpa-
tients and does not account for drugs administered 
in nursing homes and hospitals. This may lead to an 
underestimation of the adherence, even though no ef-
fect is expected on the comparison between switching 
categories. Moreover, we did not take into account 
several factors (e.g. socio-economic status, life-style) 
potentially impacting on adherence. 
CONCLUSIONS
Our study indicates that generic substitution in 
the diabetes setting does not influence patients’ 
adherence. This information is particularly useful 
when considering that even uncertainties of a nega-
tive effect on adherence may represent a disincen-
tive in using generic drugs. The fact that our find-
ings are relevant to an elderly population of complex 
patients with comorbidities supports the view that 
similar findings may be expected in other chronic 
treatments.
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